Cargando…

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS). This review describes the ECS, its role in the central nervous system, how it is dysregulated in FXS, and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palumbo, Joseph M., Thomas, Brian F., Budimirovic, Dejan, Siegel, Steven, Tassone, Flora, Hagerman, Randi, Faulk, Christopher, O’Quinn, Stephen, Sebree, Terri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830713/ https://www.ncbi.nlm.nih.gov/pubmed/36624400 http://dx.doi.org/10.1186/s11689-023-09475-z

Ejemplares similares

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Fragile X-Associated Neuropsychiatric Disorders (FXAND) in Young Fragile X Premutation Carriers
por: Aishworiya, Ramkumar, et al.
Publicado: (2022)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature
por: Tartaglia, Nicole, et al.
Publicado: (2019)

Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders
por: Trajković, Jelena, et al.
Publicado: (2022)

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
por: Protic, Dragana D., et al.
Publicado: (2022)

Neural progenitor cells from an adult patient with fragile X syndrome
por: Schwartz, Philip H, et al.
Publicado: (2005)

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Intranuclear inclusions in a fragile X mosaic male
por: Pretto, Dalyir I, et al.
Publicado: (2013)

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin‐two cases
por: Protic, Dragana, et al.
Publicado: (2019)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Sequencing the unsequenceable: Expanded CGG-repeat alleles of the fragile X gene
por: Loomis, Erick W., et al.
Publicado: (2013)

Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome
por: Jasoliya, Mittal, et al.
Publicado: (2020)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Prenatal Diagnosis of Fragile X: Can a Full Mutation Allele in the FMR1 Gene Contract to a Normal Size?
por: Manor, Esther, et al.
Publicado: (2017)

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
por: Heussler, Helen, et al.
Publicado: (2019)

Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome
por: Famula, Jessica, et al.
Publicado: (2022)

Testing the FMR1 Promoter for Mosaicism in DNA Methylation among CpG Sites, Strands, and Cells in FMR1-Expressing Males with Fragile X Syndrome
por: Stöger, Reinhard, et al.
Publicado: (2011)

Immune Dysregulation as a Cause of Autoinflammation in Fragile X Premutation Carriers: Link between FMRI CGG Repeat Number and Decreased Cytokine Responses
por: Careaga, Milo, et al.
Publicado: (2014)

Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome
por: Careaga, Milo, et al.
Publicado: (2014)

Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome
por: Chonchaiya, Weerasak, et al.
Publicado: (2010)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?
por: Protic, Dragana, et al.
Publicado: (2021)

Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation
por: Wang, Jun Yi, et al.
Publicado: (2022)

Clinical and molecular correlates in fragile X premutation females
por: Jiraanont, Poonnada, et al.
Publicado: (2017)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials
por: Duy, Phan Q., et al.
Publicado: (2017)

Fragile X Syndrome: Recent Research Updates toward Capturing Treatments’ Improvement in Clinical Trials
por: Budimirovic, Dejan B., et al.
Publicado: (2022)

Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome
por: Johnson, Devon, et al.
Publicado: (2022)

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
por: Hagerman, Randi, et al.
Publicado: (2010)

Fragile X Premutation: Medications, Therapy and Lifestyle Advice
por: Sodhi, Deepika Kour, et al.
Publicado: (2021)

Molecular Biomarkers in Fragile X Syndrome
por: Zafarullah, Marwa, et al.
Publicado: (2019)

Metformin treatment in young children with fragile X syndrome
por: Biag, Hazel Maridith B., et al.
Publicado: (2019)

Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome
por: Greco, Claudia M, et al.
Publicado: (2011)

Blood Proteome Profiling Reveals Biomarkers and Pathway Alterations in Fragile X PM at Risk for Developing FXTAS
por: Zafarullah, Marwa, et al.
Publicado: (2023)

Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid
por: Merrick, John, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lkh0k6uhjn6gpe3eshaqrqceqr